Telix Appoints David Gill as Non-Executive Director
MELBOURNE, Australia and INDIANAPOLIS, April 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May...
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®[1], Floret...
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
* Webcast and conference call to be held today, Tuesday March 10 at 9:30 a.m.
AEDT (Monday March 9 at 6:30 p.m. EDT). Investors can register at the following
link:https://s1.c-conf.com/diamondpass/10053620-ju7y6t.html
Investor Education Webinar
The Future of Prostate Imaging: What do physicians want? MELBOURNE, Australia and INDIANAPOLIS, March 2, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") invites investors to join a webinar with key opinion leaders to discuss a physician's perspective on innova...
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
MELBOURNE, Australia and INDIANAPOLIS, Feb. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces its financial results for the year ended December 31, 2025. FY 2025 key results1 Group performance2: Double-digit revenue growth and positive adju...
Telix Full Year Results 2025 Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") advises that it will release its full year results for the period ended 31 December 2025 on Friday 20 February 2026 AEDT (Thursday 19 February 2026 EST). An invest...
First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
MELBOURNE, Australia, Jan. 29, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in the Phase 3 registration study of TLX591-Px (Illuccix®, Kit for the preparation of68Ga-PSMA-11) for prostate cancer imaging i...
Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
MELBOURNE, Australia and INDIANAPOLIS, Ind., Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights * Full-year (FY) 2...
Chinese NMPA Accepts New Drug Application for Illuccix for Prostate Cancer Imaging
MELBOURNE, Australia and INDIANAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the Chinese National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) has accepted the filing of a New Drug Application (...
First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed in BiPASS™ (Biopsy of theProstate Avoidance Stratification Study), a Phase 3 trial ...
Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
MELBOURNE, Australia and INDIANAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today advises that Dr. Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the 44th Annual J.P. Morgan Healthcare Conference being held in Sa...
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: * TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase ...
Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinica...
ProstACT Global Phase 3 Update: First Patient Dosed in Randomized Treatment Expansion, Part 1 Readout Plans Confirmed
MELBOURNE, Australia and INDIANAPOLIS, Dec. 8, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient has been dosed in Part 2 (randomized treatment expansion) of its ProstACT Global Phase 3 study evaluating its lead prostate can...
Telix Opens TMS Yokohama in Japan, Commemorative Lecture Held
MELBOURNE, Australia and KYOTO, Japan, Nov. 21, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the official opening of Telix Manufacturing Solutions (TMS) inYokohama, Japan, the Company's first cyclotron facility in theAsia Pacific region (APAC...
ZIRCON-X Analysis: TLX250-CDx Impacts Clinical Decision Making for Almost Half of Patients with Indeterminate Renal Masses
MELBOURNE, Australia and INDIANAPOLIS, Nov. 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces results from the ZIRCON-X study which finds that almost half of all patients imaged with TLX250-CDx (Zircaix®[1], 89Zr-DFO-girentuximab) PET/CT[2] wo...
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89 Zr-girentuximab) in metastatic triple negative breast cancer (mTNB...
TLX250-CDx (Zircaix®) Included in Leading International Guidelines for Renal Imaging
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today welcomes updated guidelines from the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the European Association of Nuclear Medicine (EANM) and The Ame...
Telix Doses First Patient in SOLACE Trial for Metastatic Bone Pain
MELBOURNE, Australia and INDIANAPOLIS, Oct. 23, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that it has dosed the first patient in a Phase 1 clinical trial of TLX090 (153 Samarium (Sm)-DOTMP), a therapeutic radiopharmaceutical candidate for t...
Telix Reports US$206M Revenue, FY 2025 Guidance Upgraded
MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides an update on its commercial and operational performance for the quarter ended30 September 2025 (Q3 2025). All figures are in USD unless stated otherwi...
